Insights
Governance, escalation design, inspection readiness, and sponsor-side operating clarity.
- 2026-06-12
What sponsors should document when overseeing a CRO under ICH E6(R3)
A practical framework for documenting responsibilities, review, decisions, escalation, and follow-through when important trial activities are transferred to a CRO.
Read insight - 2026-06-12
How lean biotechs can maintain sponsor oversight
Lean biotech teams can maintain credible sponsor oversight with clear decision rights, focused governance, and experienced embedded support.
Read insight - 2026-06-12
Medical monitoring versus medical oversight
Medical monitoring and sponsor medical oversight overlap, but they are not interchangeable. The distinction matters for responsibilities, escalation, and documentation.
Read insight - 2026-06-12
MENA clinical trial expansion risks sponsors should plan for
Regional expansion works best when partner roles, startup dependencies, time-zone coverage, and sponsor oversight are designed before activity accelerates.
Read insight - 2026-06-12
How to build a vendor governance dashboard that drives decisions
A useful vendor dashboard turns performance signals into sponsor decisions instead of producing another status-reporting layer.
Read insight - 2026-06-11
Inspection readiness is an operating discipline
Inspection readiness is strongest when evidence of oversight and issue management is created during execution, not reconstructed at the end.
Read insight - 2026-03-18
How sponsor-side oversight reduces operational risk
A practical view of how defined ownership, escalation, and traceable decisions reduce execution risk in outsourced clinical programs.
Read insight